Fairvalue-Calculator Fairvalue-Calculator
EN DE

DV Biomed Co (6539) Fair Value & Analysis

Healthcare · TW · Market cap 1.0B TWD

Price40.95 TWD
Fair Value12.64 TWD
Upside-69.1%
Quality95/100
Evidence: High Range 10.25 TWD – 15.02 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

DV Biomed Co (6539) currently trades at 40.95 TWD, while our model-based Fair Value estimate is 12.64 TWD — implying the stock looks roughly 69.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

DV Biomed Co., Ltd. manufactures and sells medical-grade skin care products in Taiwan and China. The company provides health and slimming services; and distributes medical aesthetic fillers and aesthetic medical equipment. It also offers functional beverages and supplements, including beauty, slimming, supplements, and other products; skin care; and beauty products and services. The company was founded in 2011 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is DV Biomed Co (6539) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 12.64 TWD versus a price of 40.95 TWD — about −69% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6539?
Our 21-model fair value for DV Biomed Co is 12.64 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 40.95 TWD.
What is the quality score of 6539?
DV Biomed Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.